Lord’s Mark strengthens UK and UK allied market strategy with regulatory backing for IVD portfolio.

In an exciting development, Lord's Mark Industries has secured registration for its In-Vitro Diagnostic portfolio with the MHRA, significantly boosting market access. This follows the approval of their AI-enhanced Renalyx haemodialysis system in the UK. The firm aims for a December 2026 market launch for its IVD products, ahead of schedule, along with a planned January 2027 start for its pathology lab, highlighting its strong commitment to global healthcare integration.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hoce1DA
via IFTTT